{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.95","upperLimit":"96.58","value":"93.26"},{"groupId":"OG001","lowerLimit":"20.38","upperLimit":"96.92","value":"80.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Kaplan Meier estimate of the 3-year PFS rate is provided. PFS is the time interval measured from initiation of treatment until progression or death from any cause or until last follow-up for those who were event free at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\\>25% increase in 2D or \\>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study.","dispersionType":"95% Confidence Interval","groups":[{"description":"CSF/serum hCGbeta \\<= 50 mIU/mL","id":"OG000","title":"hCGbeta <= 50 mIU/mL"},{"description":"50 mIU/mL \\< CSF /serum hCGbeta \\<= 100 mIU/mL","id":"OG001","title":"50 mIU/mL < hCGbeta <= 100 mIU/mL"}],"paramType":"NUMBER","populationDescription":"The eligible patients with localized germinoma and CSF serum hCGbeta of 50 mIU/mL or less or CSF serum hCGbeta greater than 50 mIU/mL and less than or equal to 100 mIU/mL.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Estimation of the PFS Distribution of Patients With Localized Germinoma Patients and Cerebrospinal Fluid (CSF) Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL","type":"SECONDARY","unitOfMeasure":"percentage of patients"}